Glioblastoma Immunotherapy Trial for New Patients
Margaret’s Trial: A New Hope for Glioblastoma Patients Launched in Memory of a Determined Campaigner
Table of Contents
London, UK – A groundbreaking clinical trial, named “Margaret’s Trial” in honor of a courageous patient who campaigned tirelessly for advancements in brain cancer treatment, has officially opened, offering a beacon of hope for those diagnosed with glioblastoma, the most aggressive form of brain cancer. The trial, spearheaded by Dr. Paul Mulholland at the UCL Cancer Institute, aims to significantly improve outcomes for patients facing a disease with a historically poor prognosis.
A Sister’s Legacy: Driving Progress Against Glioblastoma
The initiative is deeply personal for Dame Siobhain McDonagh, MP for Mitcham and Morden and chair of the all-party parliamentary group on brain tumours. Her beloved sister, Margaret, was diagnosed with glioblastoma in 2023. Appalled by the lack of progress in treatment options over several decades, Margaret herself initiated a campaign to drive change.
“My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma,” said Dame Siobhain. “Changing this was margaret’s final campaign and one that I have continued in her memory. I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret’s Trial.”
A Novel Approach: Boosting the Immune System for Better Outcomes
dr. Mulholland, who met Margaret shortly after her diagnosis, was inspired by her proactive spirit. “When I met Margaret she said to me ‘what can I do to support you to cure this disease’,” he recalled. “I am incredibly grateful to her and to Siobhain, whose campaigning and fundraising in her sister’s memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis.”
The crucial element of Margaret’s Trial lies in its innovative approach: patients will have their immune system boosted by a drug before undergoing any other treatment. This strategy is designed to leverage the patient’s own immune system when they are at their fittest and most able to tolerate immunotherapy.
“We saw with Ben, the one patient recruited to the NeAT-GLIO immunotherapy study, that he has had clear scans as having the treatment and the tumour hasn’t returned more than two and a half years later,” Dr. Mulholland added, highlighting the potential of this approach. “We’re taking everything we have learned from previous trials into this new study and we are already planning follow on trials. My aim is to find a cure for glioblastoma and I am very thankful to dame Siobhain McDonagh MP, the Jon Moulton Charity Trust and The National Brain Appeal for their support on this journey.”
The power of Collaboration and Dedicated Support
The development of Margaret’s Trial is a testament to the power of collaboration between researchers,patient advocates,and charitable organisations. The National Brain Appeal is providing crucial support by funding two vital posts: a clinical nurse specialist dedicated to guiding glioblastoma patients through the complex process of diagnosis and clinical trial decisions, and a senior computational biologist. This biologist will delve into the intricate genetics of glioblastoma, working with vast datasets to analyze patient samples and research experiments, thereby accelerating understanding and treatment development.
“Our aim is to rapidly bring about improved outcomes for patients with glioblastoma by bringing together the best science, with a multidisciplinary team of clinicians, experimental scientists, bioinformaticians and the pharmaceutical industry. We want to find a cure for this devastating disease,” stated Dr. Paul Mulholland, UCL Cancer Institute.
How to Get Involved
Treatment for Margaret’s Trial will be administered at the NIHR UCLH’s Clinical Research Facility and the National Hospital for Neurology and Neurosurgery. Patients interested in learning more about the Win-Glio trial and whether it might be suitable for them are encouraged to discuss it with their treating consultant.
Source: University College London